Finance

Lists
DNLI:NASDAQ
Denali Therapeutics Inc
$18.57
+0.92%
(+0.17) 1D
Nov 19, 12:24:50 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNLI...
Open
$18.43
High
$19.00
Low
$18.37
Mkt. cap
2.98B
Avg. vol.
1.67M
Volume
512.91K
52-wk high
$27.30
52-wk low
$15.34
EPS
-$1.74
Beta
1.08
Shares outstanding
160.29M
No. of employees
507
Open
$18.43
High
$19.00
Low
$18.37
Mkt. cap
2.98B
Avg. vol.
1.67M
Volume
512.91K
52-wk high
$27.30
52-wk low
$15.34
EPS
-$1.74
Beta
1.08
Shares outstanding
160.29M
No. of employees
507
News stories
From web sources and news partners
About Denali Therapeutics Inc
CEO-
Employees507
Founded2013
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 8 analysts giving stock ratings to DNLI in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for DNLI in the last 3 months.
Highest
Current $18.57
$42.00 (+126.17%)
Average
$35.33 (+90.25%)
Lowest
$24.00 (+29.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
$37.00
+99.2%
11/13/2026
Benjamin Burnett
Wells Fargo
Buy
Initiated
$35.00
+88.5%
11/13/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$35.00
+88.5%
11/04/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
11/04/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Maintained
-
-
11/03/2026
Thomas Shrader
BTIG
Buy
Maintained
$39.00
+110%
11/03/2026
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$42.00
+126.2%
11/04/2026
Laura Chico
Wedbush
Buy
Maintained
$24.00
+29.2%
11/04/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
$29.00
+56.2%
08/11/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$42.00
+126.2%
08/07/2026
Michael Yee
UBS
Buy
Reiterated
$34.00
+83.1%
08/07/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$41.00
+120.8%
08/07/2026
Charles Moore
Robert W. Baird
Buy
Maintained
$34.00
+83.1%
08/07/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/06/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/07/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
$41.00
+120.8%
07/20/2026
David Hoang
Deutsche Bank
Buy
Reiterated
$35.00
+88.5%
07/16/2026
Unknown Analyst
Jefferies
Buy
Maintained
$40.00
+115.4%
07/13/2026
Jay Olson
Oppenheimer
Buy
Maintained
$40.00
+115.4%
05/11/2026
Rudy Li
Wolfe Research
Hold
Initiated
-
-
02/23/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
-$0.66 / -$0.37
-79.32%miss
Revenue / Est. (USD)
17.78M / 25.54M
-30.39%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
3.60M
17.78M
Cost of goods sold
97.90M
103.85M
97.11M
106.29M
Cost of revenue
97.90M
103.85M
97.11M
106.29M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.46M
33.51M
36.28M
37.48M
Operating expense
39.46M
33.51M
36.28M
37.48M
Total operating expenses
137.36M
137.36M
133.40M
143.78M
Operating income
-137.36M
-137.36M
-129.79M
-126.00M
Other non operating income
-
-
-
-
EBT including unusual items
-128.45M
-128.45M
-127.55M
70.13M
EBT excluding unusual items
-130.09M
-129.71M
-126.80M
-123.12M
Income tax expense
102.00K
-
-
-
Effective tax rate
-0.08%
-
-
-
Other operating expenses
-
-
-
-
Net income
-128.55M
-128.45M
-127.55M
70.13M
Net profit margin
-
-
-3,539.21%
394.45%
Earnings per share
-0.73
-0.69
-0.68
-0.66
Interest and investment income
7.28M
7.83M
3.17M
3.05M
Interest expense
-
-179.00K
-178.00K
-177.00K
Net interest expenses
7.28M
7.65M
2.99M
2.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
-133.58M
-133.60M
-125.31M
-121.51M
Gain or loss from assets sale
-
-
-
-194.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps